Sort
21,281 grants matching “influenza”
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$2,018,048David S Stephens · Emory University · UM1 · FY2022 · AI
Center for Biomedical Research Excellence in Pathogen-Host Interactions
$2,016,391Stephen B Pruett · Mississippi State University · P20 · FY2015 · GM
Immunology Core
$2,016,247Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIC · FY2015 · AI
Immunology Core
$2,016,247Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIC · FY2014 · AI
Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012
$2,014,564Lisa A Jackson · Kaiser Foundation Research Institute · UM1 · FY2021 · AI
Disordered Proteostasis as a Driver of Disease in the Aging Lung
$2,014,421Gr Scott Budinger · Northwestern University At Chicago · P01 · FY2015 · AG
Tomotherapy and Hematopoietic Stem Cells For Tolerance to Kidney Transplants
$2,013,897Dixon B Kaufman · University Of Wisconsin-Madison · U01 · FY2012 · AI
Influenza and Emerging Infectious Diseases
$2,009,368Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Adeno-associated Virus Biology And Utilization For Gene Transfer
$2,008,334John A Chiorini · National Institute Of Dental & Craniofacial Research · ZIA · FY2013 · DE
IL-15-MEDIATED IL-6RA EFFECTOR MEMORY CD8+T CELLS IN DYSFUNCTIONAL LUNG RESPONSES DURING CIGARETTE SMOKE EXPOSURE AND INFLUENZA VIRAL INFECTIONS
$2,006,945Yale Univ · · FY2019 · Department of the Army
Center for Biomedical Research Excellence in Pathogen-Host Interactions
$2,006,213Stephen B Pruett · Mississippi State University · P20 · FY2014 · GM
Emerging Infections Program
$2,003,801Timothy F. Jones · Tennessee State Department Of Health · U01 · FY2008 · CI
Task A44: Ferret Models for the Evaluation of Universal Influenza Vaccines and Vaccine Strategies
$2,001,804Kevin Walters · Southern Research Institute · N01 · FY2021 · AI
Development/production of universal influenza vaccines
$2,001,000Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2022 · AI
Mali International Center for Excellence in Research: Vectors and Hosts of Parasitic Infectious Diseases
$2,000,083Tovi Lehmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Development of Fludase for Prevention of Influenza
$2,000,000Mang Yu · Nexbio, Inc. · R44 · FY2007 · AI
Neuroimmune Mechanisms of Psychiatric Disorders
$2,000,000Cameron S. Carter · University Of California At Davis · P50 · FY2015 · MH
Development of Fludase for Prevention of Influenza
$2,000,000Nexbio, Inc. · R44 · FY2005 · AI
Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$2,000,000Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2022 · IP
Prospective Cohort to Assess Novel and Repeated SARS-CoV-2 Infection and COVID-19 Illness within a US State or Region
$2,000,000National Cancer Institute · Y01 · FY2021 · CA
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$2,000,000Rangaraj Selvarangan · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2025 · IP
Infectious Diseases Clinical Research Program
$2,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2009 · AI
Development of Fludase for Prevention of Influenza
$2,000,000Mang Yu · Nexbio, Inc. · R44 · FY2006 · AI
Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).
$2,000,000Manjusha Gaglani · Baylor Research Institute · U01 · FY2022 · IP
Neuroimmune Mechanisms of Psychiatric Disorders
$2,000,000Cameron S. Carter · University Of California At Davis · P50 · FY2017 · MH